Viewing Study NCT07241793


Ignite Creation Date: 2025-12-25 @ 1:18 AM
Ignite Modification Date: 2025-12-25 @ 11:27 PM
Study NCT ID: NCT07241793
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2025-09-24
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Sponsor: Sun Yat-sen University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module